Wall Street Journal opinion: “not a single published study has demonstrated that patients with a prior infection benefit from Covid-19 vaccination. That this isn’t readily acknowledged by the CDC or Anthony Fauci is an indication of how deeply entangled pandemic politics is in science.”
14th June 2021: We’ve spent two days scouring the internet looking for Plan B for what happens in the event of complete Covid-19 vaccine failure. So what does happen if the vaccines fail? Here is what we have found so far:
Actually, we found no results. It seems that no one is even asking the question. Perhaps it’s time to start that conversation?
** UPDATE 31ST JULY 2021 ** Finally, the UK government takes a peek out of the front screen to see what is oncoming rather than checking the rear-view mirror to look at the pile-up that has just occurred.
*Warning* The report contains plenty of dire predictions but proposes no solutions whatsoever.
** UPDATE 15th AUGUST 2021 **
“UK Ministers are being pressed to reveal what contingency plans are in place to deal with a future Covid variant that evades current vaccines, amid warnings from scientific advisers that such an outcome could set the battle against the pandemic back a year or more.”
** UPDATE 27th AUGUST 2021 **
If you have two hours to waste, you could spend it reading this new European view on the future of Sars-CoV-2:
In our opinion, this article is by far the poorest attempt yet to predict the future course of the pandemic, relying largely on outdated information and stale groupthink. For example:
“What can be expected in the autumn and winter of 2021 depends substantially on what happens in the summer; specifically, the success of vaccination programs both in Europe and worldwide, and the emergence and spread of (new) VOCs. Compared to the summer, autumn and winter bring the additional complication of unfavorable seasonal effects. The seasonality of coronaviruses is expected to increase infections in the autumn and winter months…..”
It’s a 0/10 from us.
** UPDATE 14TH SEPTEMBER 2021 **
The UK has another stab at Plan B:
Er, yeah, I guess we’ll keep searching…
Researchers reported that among 20 fully-vaccinated healthcare workers with vaccine breakthrough COVID-19 cases, all were infected with coronavirus variants. An earlier study had linked breakthrough infections with low viral loads, suggesting low transmission risks, but “we found many samples in our breakthrough cohort with high viral load,” said coauthor Pavitra Roychoudhury of the University of Washington. CONTAGIOUS: “Our work suggests that not all breakthrough infections are at low risk of initiating transmission and, if they did, these infections could lead to the continued spread of variants of concern, particularly in areas with low vaccination rates.”
The CDC has genetic data for virus samples from 555 vaccine breakthrough infections. Mutated variants of the coronavirus, including those first seen in the UK and South Africa, accounted for 64% of the breakthroughs.
Medrxix preprint – Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State
FT: “the vaccines send the DNA gene sequences of the spike protein into the cell … Once inside the cell nucleus, certain parts of the spike protein splice, or split apart“
During the last months many countries have started the immunization of millions of people by using vector-based vaccines. Unfortunately, severe side effects became overt during these vaccination campaigns: cerebral venous sinus thromboses (CVST), absolutely rare under normal life conditions, were found as a severe side effect that occured 4-14 days after first vaccinations. Besides CVST, Splanchnic Vein Thrombosis (SVT) was also observed. This type of adverse event has not been observed in the clinical studies of AstraZeneca, and therefore led immediately to a halt in vaccinations in several european countries.
These events were mostly associated with thrombocytopenia, and thus, similar to the well-known Heparin-induced thrombocytopenia (HIT). Meanwhile, scientists have proposed a mechanism to explain this vaccine-induced thrombocytopenia. However, they do not provide a satisfactory explanation for the late thromboembolic events. Here, we present data that may explain these severe side effects which have been attributed to adenoviral vaccines.
According to our results, transcription of wildtype and codon-optimized Spike open reading frames enables alternative splice events that lead to C-terminal truncated, soluble Spike protein variants. These soluble Spike variants may initiate severe side effects when binding to ACE2-expressing endothelial cells in blood vessels. In analogy to the thromboembolic events caused by Spike protein encoded by the SARS-CoV-2 virus, we termed the underlying disease mechanism the “Vaccine-Induced Covid-19 Mimicry” syndrome (VIC19M syndrome).
Researchgate paper “Vaccine-Induced Covid-19 Mimicry Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines”.
FT Article “Scientists claim to have solved Covid vaccine blood-clot puzzle”
Scientists at the Indian National Institute of Virology (NIV), Pune, have found that both Covaxin and Covishield produce half as many antibodies against the B.1.617 variant of the novel coronavirus as against the ‘original’ B.1 variant.
The scientists conducted their studies with blood sera (plural of serum, the fluid part of the blood) obtained from people who had received either two doses of *Covaxin or two doses of *Covishield. They were motivated by the need to understand how the vaccines’ efficacies varied against infections due to newer strains of the virus. The B.1.617 variant – made up of three sub-lineages – is accounting for more cases in India. The UK recently elevated the B.1.617.2 sub-lineage as a ‘variant of concern’.
*Covaxin was developed by Indian pharmaceutical company Bharat Biotech in collaboration with the Indian Council of Medical Research
*Covishield is India’s version of the Oxford-AstraZeneca vaccine manufactured in Pune by the Serum Institute of India